logo
Phanes Therapeutics announces first patient dosed in clinical study of mavrostobart (PT199) in combination with chemotherapy

Phanes Therapeutics announces first patient dosed in clinical study of mavrostobart (PT199) in combination with chemotherapy

SAN DIEGO, May 27, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the clinical study of mavrostobart (PT199) in combination with chemotherapy.
Mavrostobart is an anti-CD73 monoclonal antibody with a differentiated mechanism of action and is designed to counter the adenosine-mediated immunosuppressive tumor microenvironment (TME). Mavrostobart fully inhibits the enzyme activities of both soluble and membrane-bound CD73, unlike several other anti-CD73 antibodies which exhibit incomplete inhibition. Moreover, at higher concentrations, no loss of inhibition or 'hook effect' is observed with mavrostobart. Hence, mavrostobart addresses the limitations of current CD73 inhibitors and is expected to increase antitumor immune activation, and potentially offer a new treatment option for cancer patients.
The multi-center Phase I/II clinical trial of mavrostobart (NCT05431270), known as the MORNINGSTAR study, is currently evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of mavrostobart alone and in combination with a PD-1 Inhibitor or chemotherapy. A Phase I clinical trial of mavrostobart is also ongoing in China (CTR20242381).
ABOUT PHANES THERAPEUTICS
Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in oncology. Currently, it is conducting three Phase I/II clinical trials, including the MORNINGSTAR study with its best-in-class monoclonal antibody (mAb) program, mavrostobart (PT199), the TWINPEAK study with spevatamig (PT886) and the SKYBRIDGE study with peluntamig (PT217). Both spevatamig and peluntamig are first-in-class bispecific antibodies and have been granted orphan drug designations as well as Fast Track designations by the FDA.
The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbody®, SPECpair® and ATACCbody® to develop novel biologics that address high unmet medical needs in cancer.
For more information about Phanes Therapeutics, please visit www.phanesthera.com
For business development or media inquiries, please contact [email protected] or [email protected], respectively.
View original content to download multimedia: https://www.prnewswire.com/news-releases/phanes-therapeutics-announces-first-patient-dosed-in-clinical-study-of-mavrostobart-pt199-in-combination-with-chemotherapy-302464552.html
SOURCE Phanes Therapeutics, Inc.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

China proposes global cooperation body on AI
China proposes global cooperation body on AI

Yahoo

time5 hours ago

  • Yahoo

China proposes global cooperation body on AI

SHANGHAI, July 27, 2025 /PRNewswire/ -- A news report from The Chinese government has proposed the establishment of a world AI cooperation organization as part of its efforts to bolster open, inclusive and equitable artificial intelligence development and governance globally. Premier Li Qiang announced the initiative when addressing the opening ceremony of the 2025 World AI Conference and High-Level Meeting on Global AI Governance in Shanghai. Li emphasized the need for collaborative approaches to global AI governance to ensure that intelligent technologies are developed for the good of all. More than 1,000 high-level representatives from upwards of 40 countries and international organizations attended the opening ceremony of the three-day event, themed "Global Solidarity in the AI Era". Li said that the risks and challenges brought by AI development, such as machine hallucinations, deep fakes and AI proliferation, have aroused widespread attention. There is an urgent need to further consolidate a societal consensus on how to achieve a balance between development and security in the AI sector, he said. Li said greater emphasis should be placed on collective governance to ensure that AI ultimately benefits humanity. Given that global AI governance appears fragmented, it is essential to enhance coordination and alignment among countries around the world to establish a framework and rules for global AI governance with a broad consensus, he added. Noting that China places great importance on global AI governance and actively participates in promoting multilateral and bilateral cooperation in this regard, the premier said the nation is willing to offer more Chinese solutions to the international community and contribute more Chinese wisdom to global AI governance. In 2023, China proposed the Global AI Governance Initiative to promote an open, inclusive and fair approach to the development and governance of AI technologies. Last year, China proposed the AI Capacity-Building Action Plan for Good and for All to bridge the AI and digital divides, and to ensure the Global South benefits equitably from AI development. China actively promotes open source development, and is willing to collaborate with countries around the world to promote progress in software and hardware technologies, intensify open source initiatives, and collectively propel AI development to higher levels, Li said. Also on July 26, the conference adopted the Global AI Governance Action Plan, which calls on all parties to work in solidarity to advance AI development and governance. For more information: View original content to download multimedia: SOURCE Sign in to access your portfolio

GameSquare Regains Compliance with Nasdaq's Minimum Bid Price Requirement
GameSquare Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Miami Herald

time6 hours ago

  • Miami Herald

GameSquare Regains Compliance with Nasdaq's Minimum Bid Price Requirement

FRISCO, TX / ACCESS Newswire / July 25, 2025 / GameSquare Holdings, Inc. (NASDAQ:GAME) today announced that it received formal written confirmation from The Nasdaq Stock Market, LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq's minimum bid price requirement. To regain compliance with the Minimum Bid Price Requirement, the Company's common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. The closing bid price of the shares has been at $1.00 per share or greater for 10 consecutive business days from July 8 to July 21, 2025. Accordingly, Nasdaq Listing Qualifications Staff has notified the Company that it has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), and the matter is now closed. About GameSquare Holdings, Inc. GameSquare (NASDAQ: GAME) is a cutting-edge media, entertainment, and technology company transforming how brands and publishers connect with Gen Z, Gen Alpha, and Millennial audiences. With a platform that spans award-winning creative services, advanced analytics, and FaZe Clan, one of the most iconic gaming organizations, we operate one of the largest gaming media networks in North America. Complementing our operating strategy, GameSquare operates a blockchain-native Ethereum treasury management program designed to generate onchain yield and enhance capital efficiency, reinforcing our commitment to building a dynamic, high-performing media company at the intersection of culture, technology, and next-generation financial innovation. To learn more, visit Forward-Looking Statements: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the Company's future performance, revenue, growth and profitability; and the Company's ability to execute on its current and future business plans. These forward-looking statements are provided only to provide information currently available to us and are not intended to serve as and must not be relied on by any investor as, a guarantee, assurance or definitive statement of fact or probability. Forward-looking statements are necessarily based upon a number of estimates and assumptions which include, but are not limited to: the Company's ability to grow its business and being able to execute on its business plans, the success of Company's vendors and partners in their provision of services to the Company, the Company being able to recognize and capitalize on opportunities and the Company continuing to attract qualified personnel to supports its development requirements. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the Company's ability to achieve its objectives, the Company successfully executing its growth strategy, the ability of the Company to obtain future financings or complete offerings on acceptable terms, failure to leverage the Company's portfolio across entertainment and media platforms, dependence on the Company's key personnel and general business, economic, competitive, political and social uncertainties. These risk factors are not intended to represent a complete list of the factors that could affect the Company which are discussed in the Company's most recent MD&A. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. GameSquare assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. GameSquare Corporate Contact Lou Schwartz, PresidentPhone: (216) 464-6400Email: ir@ GameSquare Investor Relations Andrew BergerPhone: (216) 464-6400Email: ir@ GameSquare Media Relations Chelsey Northern / The UntoldPhone: (254) 855-4028Email: pr@ SOURCE: GameSquare Holdings, Inc.

Strategist's two stocks to buy (and one to skip)
Strategist's two stocks to buy (and one to skip)

Yahoo

time6 hours ago

  • Yahoo

Strategist's two stocks to buy (and one to skip)

There are thousands of stocks for investors to choose from to invest money in. Morningstar chief US market strategist David Sekera tells Market Domination Overtime Host Josh Lipton two he thinks are worth buying and one investors may want to avoid. Find out what they are and the reasons for his call in the video above. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. I just think the market in the short term has just gotten to be a little overly complacent, starting to see some signs of excess speculation, you know, meme stocks starting to make a comeback, short squeezes. I actually just heard about a resurgence in SPACs. You know, we haven't seen those for years at this point, you know, an increase in call buying. So in my mind, you know, still market weight overall. I think positioning is more important than ever, but I do think it's a good time to look to take profits where stocks have rebounded too far too fast off those April lows. You know, April 7th on the morning filter, which is my, you know, weekly podcast, is when I'd officially moved to an overweight. So at this point, I just don't see the tailwinds to really continue to keep pushing the market that much higher here in the short term. You know, you were talking about the ease earlier, you know, when we look at the US economic growth, our economic team expects the US economy to slow sequentially, you know, for the next three quarters. Of course, we have, you know, the tariff negotiations going on. I think it's really going to be all about with China. China, of course, is not going to roll over on these negotiations. I think that's going to be hard fought. Not getting a tailwind from long-term interest rates. They're still kind of in that trading range in the mid fours. You know, inflation still moderate, but again, that's going to come up later this year as the tariffs, you know, start to hit. And for now, I think the Fed's on hold. So again, I'm not seeing those tailwinds really to get the market to continue moving up that much more. So, good time to take some profit taking, but then also, as you talked about earlier, move into some of those, you know, low valuation stocks.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store